Prime editing shows proof of concept for treating sickle cell disease

(Press-News.org) (MEMPHIS, Tenn. – April 17, 2023) Sickle cell disease (SCD) is a serious blood disorder affecting millions of people, primarily those of African descent. A mutation in the gene that encodes a subunit of the oxygen-carrying molecule, hemoglobin, causes the disease. Scientists at St. Jude Children’s Research Hospital and the Broad Institute of MIT and Harvard showed a precise genome editing approach, prime editing, can change mutated hemoglobin genes back to their normal form in SCD patient cells, which restores normal blood parameters after transplantation into mice. The findings were published today in Nature Biomedical Engineering.

 

Scientists have rapidly developed technologies to edit DNA, including Cas9 nucleases and base editors, to treat genetic diseases. The study’s researchers demonstrated how a “third-generation” programmable gene editing technology called prime editing could convert the mutation that causes SCD into the normal DNA sequence, thereby rescuing the disease.

 

“Prime editing is a promising approach because, in theory, we can directly correct disease mutations to specific healthy DNA sequences of our choosing,” said co-corresponding author Jonathan Yen, Ph.D., St. Jude Department of Hematology. “We optimized prime editing in long-term blood stem cells and showed that the prime editing cells maintain full engraftment efficiency in an animal with a clinically relevant system.”

 

“These results show efficient prime editing of blood stem cells and that the prime-edited cells maintain their full ability to engraft and repopulate the bone marrow of an animal,” said senior and co-corresponding author David Liu, Ph.D., Richard Merkin, Professor at Broad Institute of MIT and Harvard, whose lab invented prime editing in 2019. “Bringing the ‘search-and-replace’ versatility of prime editing to blood stem cells raises the possibility of applying this technology to treat a wide range of diseases involving blood cells.”

 

Fixing the mutation that causes sickle cell disease

 

The researchers showed that the prime editing system could find the disease-causing mutation in the adult hemoglobin gene with high specificity and replace it efficiently with the healthy DNA sequence variant carried by most humans. Prime editing successfully corrected this mutation with up to 41% conversion in blood stem cells from SCD patients. Previous research has shown that editing over 20% of cells likely translates to therapeutic benefit.

 

Adding to the approach’s therapeutic promise is the observation that when the researchers transplanted prime-edited cells from four SCD patients into mice, normal hemoglobin production was present in about 45% of circulating red blood cells, even up to 17 weeks later. After the transplant, when placed in low-oxygen environments, the red blood cells isolated from the mouse bone marrow reduced sickling by half, from about 67% to 37%.

 

Improving precision gene editing

 

“We have identified what might be the next wave of therapies for genetic anemias,” said co-author Mitchell Weiss, M.D., Ph.D., St. Jude Department of Hematology chair. “We took the newest cutting-edge genetic engineering technology and showed that we could make meaningful gene edits for future therapies.”

 

While the scientists conducted the research in SCD patient cells transplanted into mice, the approach may have advantages over current genome editing methods used in clinical trials, such as Cas9 nucleases, which make double-stranded breaks in DNA that prime editing largely avoids. The collaborators had previously shown base editing, an alternative genome editing technology, could turn the sickle cell mutation into a benign variant, but not the original healthy sequence, in a 2021 Nature publication. The current study showed prime editing could turn the disease mutation into the original normal gene variant through a T-to-A conversion, which base editing cannot make.

 

Though the study showed the potential benefits of using prime editing to cure genetic anemias, it also showed limitations. Prime editing requires a time-consuming process to adapt and optimize each step of the protocol, such as designing the prime editing guide RNAs (pegRNAs) that target the prime editing system to the right DNA region and specify the desired edit.

 

Safety first

 

Safety remains a concern for all genomic editing technologies, especially novel approaches. While the current study, consistent with other labs’ reports on prime editing, showed virtually no off-target prime editing, it could have unforeseen safety issues as a newer gene editing technology.

 

“We are doing our best to predict toxicity, but we won’t know the true extent of the risks of this therapy until it is used in patients,” said Weiss.

 

Even with these challenges, the scientists are optimistic about the future of prime editing.

 

“Because of its unique versatility, prime editing has the potential to cure many more genetic diseases,” Yen said. “It will be a challenge to get to the clinic. It will require extensive manufacturing development, process optimization and safety assessment. But the proof of concept is there. Our work now opens the door to developing cures for many hematological diseases.”

 

Authors and funding

The study’s first author is Kelcee Everette, a graduate student in Liu’s laboratory at the Broad Institute, who participated in the St. Jude Collaborative Research Consortium for Sickle Cell Disease to advance the work. Other authors are Rachel Levine, Kalin Mayberry, Yoonjeong Jang, Thiyagaraj Mayuranathan, Nikitha Nimmagadda, Erin Dempsey, Yichao Li, Senthil Bhoopalan and Yong Cheng, all of St. Jude; Gregory Newby, Jessie Davis, Andrew Nelson, Peter Chen and Alexander Sousa, Broad Institute; and Xiong Liu and John Tisdale, National Heart, Lung, and Blood Institute and the National Institute of Diabetes and Digestive and Kidney Diseases.

 

The study was supported by grants from the National Institutes of Health (U01 AI142756, RM1 HG009490, R35 GM118062, R01 HL156647, R01 HL136135, P01 HL053749 and P30 CA21765), the Bill and Melinda Gates Foundation, the Howard Hughes Medical Institute (Helen Hay Whitney Postdoctoral Fellowship), the St. Jude Collaborative Research Consortium for Sickle Cell Disease, the National Science Foundation GRFP fellowships and ALSAC, the fundraising and awareness organization of St. Jude.

 

St. Jude Media Relations Contacts

 

Michael Sheffield
Desk: (901) 595-0221
Cell: (901) 379-6072
michael.sheffield@stjude.org
media@stjude.org

 

Emily Gest

Desk: (901) 595-0260

Cell: (901) 568-9869

emily.gest@stjude.org

media@stjude.org

 

St. Jude Children's Research Hospital

St. Jude Children's Research Hospital is leading the way the world understands, treats and cures childhood cancer, sickle cell disease and other life-threatening disorders. It is the only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. Treatments developed at St. Jude have helped push the overall childhood cancer survival rate from 20% to 80% since the hospital opened more than 60 years ago. St. Jude shares the breakthroughs it makes to help doctors and researchers at local hospitals and cancer centers around the world improve the quality of treatment and care for even more children. To learn more, visit stjude.org, read St. Jude Progress blog, and follow St. Jude on social media at @stjuderesearch.

 

Broad Institute of MIT and Harvard

Broad Institute of MIT and Harvard was launched in 2004 to empower this generation of creative scientists to transform medicine. The Broad Institute seeks to describe the molecular components of life and their connections; discover the molecular basis of major human diseases; develop effective new approaches to diagnostics and therapeutics; and disseminate discoveries, tools, methods and data openly to the entire scientific community.

 

Founded by MIT, Harvard, Harvard-affiliated hospitals, and the visionary Los Angeles philanthropists Eli and Edythe L. Broad, the Broad Institute includes faculty, professional staff and students from throughout the MIT and Harvard biomedical research communities and beyond, with collaborations spanning over a hundred private and public institutions in more than 40 countries worldwide.

 

 

END